Ceftaroline (Teflaro) | GlobalRPh Renal Dosing Master

READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Use the renal measure and units named by this source. Confirm product, indication, age, stable versus changing kidney function, and exact dialysis modality. The selected summary is not a complete prescribing monograph. Renal method and dosing checklist

Choose a source to read (4)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

1 additional source qualifications - review before use

Teflaro - product and source limitations

The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

Before applying: Apply only to the stated formulation, indication and renal population.

Also check: Teflaro - product and source limitations

Official source

Teflaro - labeled renal guidance

Renal action and limits

Ceftaroline fosamil (Teflaro), adult IV infusion
Cockcroft-Gault CrCl, mL/min

Action or finding: Adult IV ceftaroline doses every 12 hours are 400 mg at CrCl above 30 through 50, 300 mg at 15 through 30, and 200 mg below 15 mL/min, including ESRD on HD. Administer after HD on dialysis days.
Limits and monitoring: The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.
Before use: Apply only to the stated formulation, indication and renal population.

DailyMed SPL version 43, posted Nov 17, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.

Jump to the dose table for this product

Choose a product and source Teflaro | GlobalRPh RX passage All evidence

Product / population: Ceftaroline fosamil (Teflaro), adult IV infusion
Renal measure: Cockcroft-Gault CrCl, mL/min
Source revision: DailyMed SPL version 43, posted Nov 17, 2025
Retrieved: 2026-11-07 (not the revision date)

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Renal guidance: 2, adult renal impairment dosing table

Limits that apply to these rows

The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

Adult indication-specific ceftaroline renal regimens
Cockcroft-Gault CrCl (mL/min)	Adult IV dose
>30 to 50	400 mg every 12 hours
15 to 30	300 mg every 12 hours
<15, including ESRD	200 mg every 12 hours; after HD on dialysis days

Read the retained text before reformatting

Adult IV ceftaroline doses every 12 hours are 400 mg at CrCl above 30 through 50, 300 mg at 15 through 30, and 200 mg below 15 mL/min, including ESRD on HD. Administer after HD on dialysis days. The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

Source revision: DailyMed SPL version 43, posted Nov 17, 2025 | Retrieved: 2026-11-07. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ecde48b-75a2-4beb-9999-369f3f61bb8a

Scope: Selected renal passages reviewed; independent clinician adjudication pending. GlobalRPh v7.4.

Full source card / provenance

All sources, comparison tools and evidence navigation

Added / rechecked in v7.4

Read source findings

Read source-specific summaries and their qualifications. Retrieval date is not label revision date. Recent review does not imply clinical approval.

Official

Teflaro - labeled renal guidance

Retrieved: 2026-11-07
Source revision: DailyMed SPL version 43, posted Nov 17, 2025

Renal measure: Cockcroft-Gault CrCl, mL/min

Read this dated source finding

Rxlist

Teflaro - selected RX renal passage

Retrieved: 2026-11-07
Source revision: Mirror revision not established in the reviewed passage.

Renal measure: Use the renal measure explicitly present in the RX passage.

Read this dated source finding

See all retained evidence sources

Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Read 1 source difference / applicability notes

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal result Open this source quick answerOpen original reference

Official product label

Teflaro - labeled renal guidance

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Ceftaroline fosamil (Teflaro), adult IV infusion

Renal method: Cockcroft-Gault CrCl, mL/min
Retrieved: 2026-11-07

Read local renal result Open this source quick answerOpen original reference

GlobalRPh RX List

Teflaro - selected RX renal passage

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Ceftaroline fosamil (Teflaro), adult IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Retrieved: 2026-11-07

Read local renal result Open this source quick answerOpen original reference

Professional guidance

UCSF - ceftaroline: standard and severe-infection schedules

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Retrieved: 2026-09-05

Read local renal result Open this source quick answerOpen original reference

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Product / population check

Confirm the exact formulation before using a renal source

These links compare product identities, not interchangeable doses. A selected summary is not a complete prescribing monograph.

Source-specific review points

Teflaro - product and source limitations

Read the attributed comparison notes and source cards below. No conflict has been silently adjudicated.

Source-quality holds

Find text within this drug

Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. This in-page search is processed in your browser. Do not enter patient identifiers; advertising scripts also run on this page.

All source summaries, original wording and provenance

Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources

Jump to renal guidance Read 1 difference / caution notes Clinician guide

First sourceSecond source

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Source-review outline (read-only; copy and complete elsewhere)

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Population Kidney-function trend Renal replacement setting

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Read before choosing a regimen

Source differences and product cautions

Search differences across all drugs

These are specific issues found during source review, not an automated judgment that one source is universally correct. A label mirror and its original label are not independent evidence.

Source scope / renal recommendation differences

Teflaro - product and source limitations

The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

How to use this: Apply only to the stated formulation, indication and renal population.

Teflaro - labeled renal guidance Teflaro - selected RX renal passage

Selected renal passages reviewed; independent clinician adjudication pending.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Independent clinical review is pending. These selected summaries are not an approved institutional dosing protocol. Confirm the exact product, the complete current source and local policy before use.

Official source

Teflaro - labeled renal guidance

Ceftaroline fosamil (Teflaro), adult IV infusion

Method: Cockcroft-Gault CrCl, mL/min

Renal guidance: 2, adult renal impairment dosing table Read this complete source summary

Rxlist source

Teflaro - selected RX renal passage

Ceftaroline fosamil (Teflaro), adult IV infusion

Method: Use the renal measure explicitly present in the RX passage.

RX List: selected renal passage Read this complete source summary

Professional source

UCSF - ceftaroline: standard and severe-infection schedules

Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Method: CrCl in mL/min where specified; no equation inferred.

Dosing / renal protocol and limits Read this complete source summary

Preserved GlobalRPh source

Original GlobalRPh protocol and comments

Preserved source. Not revalidated as current labeling.

Method: Use the measure stated in the original section.

Usual Dosing (Adults)Renal Dosing Hemodialysis Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scope Teflaro - labeled renal guidance Teflaro - selected RX renal passage UCSF - ceftaroline: standard and severe-infection schedules

Choose two source checkboxes below.

Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Compare original content

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. Read the original source for its complete context: https://globalrph.com/renal/ceftaroline/

Indications and usage

Teflaro (ceftaroline fosamil) is indicated for acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible S. aureus (including methicillin-susceptible and methicillin-resistant isolates), S. pyogenes, S. agalactiae, E. coli, K. pneumoniae and K. oxytoca.

Community-acquired bacterial pneumonia (CABP): S. pneumoniae (including concurrent bacteremia), S. aureus (methicillin-susceptible isolates only), H. influenzae, K. pneumoniae, K. oxytoca and E. coli.

Use only for proven or strongly suspected susceptible bacterial ABSSSI or CABP. Obtain appropriate specimens to isolate and identify causative organisms and determine susceptibility. When available, culture and susceptibility information should guide selection or modification; otherwise local epidemiology and susceptibility patterns may contribute.

GRPH-ceftaroline-01 · Source section: Indications and usageRenal section finder

Usual Dosing (Adults)

Adults >=18 years: 600 mg IV every 12 hours, infused over 1 hour. Duration is guided by severity/site and clinical and bacteriological progress: ABSSSI 5 to 14 days; CABP 5 to 7 days.

GRPH-ceftaroline-02 · Source section: Usual Dosing (Adults)Renal section finder

Renal Dosing

Cockcroft-Gault creatinine clearance:

CrCl (mL/min)	Dose
>50	No adjustment
>30 to <=50	400 mg IV over 1 hour every 12 hours
>=15 to <=30	300 mg IV over 1 hour every 12 hours
ESRD <15, including hemodialysis	200 mg IV over 1 hour every 12 hours

GRPH-ceftaroline-03 · Source section: Renal DosingRenal section finder

Hemodialysis

Teflaro is hemodialyzable. Administer after hemodialysis on dialysis days.

GRPH-ceftaroline-04 · Source section: HemodialysisRenal section finder

Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official Compare this source

Teflaro - labeled renal guidance

Open original reference

Open / share this exact local source

DailyMed / product prescribing information · Ceftaroline fosamil (Teflaro), adult IV infusion

Renal method: Cockcroft-Gault CrCl, mL/min
Source date: DailyMed SPL version 43, posted Nov 17, 2025
Retrieved: 2026-11-07

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

Renal guidance: 2, adult renal impairment dosing table

Limits that apply to these rows

The pediatric table uses a different renal metric. Confirm the patient's age, indication and infusion instructions.

Adult indication-specific ceftaroline renal regimens
Cockcroft-Gault CrCl (mL/min)	Adult IV dose
>30 to 50	400 mg every 12 hours
15 to 30	300 mg every 12 hours
<15, including ESRD	200 mg every 12 hours; after HD on dialysis days

Read the retained text before reformatting

RDM74-teflaro-official-1 · Source locator: Renal guidance: 2, adult renal impairment dosing table

Source identity and provenance

Source family: product_label
Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=3ecde48b-75a2-4beb-9999-369f3f61bb8a
Retrieved: 2026-11-07
Renal-function method: Cockcroft-Gault CrCl, mL/min
Source date/version: DailyMed SPL version 43, posted Nov 17, 2025
Hash meaning: SHA-256 of the local selected-source summary
Local summary SHA-256: 3e2a602db6d6a0181fded404e6cc0d318e5f5284745a5f89da42d77aee0287cf

Locally imported selected renal sections

GlobalRPh RX List renal information

Rxlist Compare this source

Teflaro - selected RX renal passage

Open original reference

Open / share this exact local source

GlobalRPh RX List / product-label mirror · Ceftaroline fosamil (Teflaro), adult IV infusion

Renal method: Use the renal measure explicitly present in the RX passage.
Source date: Mirror revision not established in the reviewed passage.
Retrieved: 2026-11-07

Label mirror, not independent corroboration. This is selected locally stored RX List content. Full monograph import and current official-label review are not implied.

Dose or interval guidance. Use only the product, indication, renal metric and population described in this source.

Selected renal passages reviewed; independent clinician adjudication pending.

RX List: selected renal passage

The mirror identifies the adult moderate, severe, and ESRD dose-reduction bands and includes hemodialysis.

RDM74-teflaro-rxlist-1 · Source locator: RX List: selected renal passage

Source-specific limits

This mirror and the underlying product label share a source family.

Source identity and provenance

Source family: product_label_mirror
Source: https://globalrph.com/rx-list/teflaro-drug/
Retrieved: 2026-11-07
Renal-function method: Use the renal measure explicitly present in the RX passage.
Source date/version: Mirror revision not established in the reviewed passage.
Hash meaning: SHA-256 of the local selected-source summary
Local summary SHA-256: 3c2c4d3335af17ce864b5ce468211a155808556866692e847fb997267e96e5fe

Separate professional-source layer

University and professional protocols

Professional Compare this source

UCSF - ceftaroline: standard and severe-infection schedules

Open original reference

Open / share this exact local source

UCSF Infectious Diseases Management Program · Adults; source-specific institutional guidance. Match route, indication and renal replacement modality.

Renal method: CrCl in mL/min where specified; no equation inferred.
Source date: Revision date not stated in the reviewed page.
Retrieved: 2026-09-05

Locally included source-specific summary. Regimen differences are not automatically resolved.

Dosing / renal protocol and limits

Limits that apply to these rows

Printed bands overlap at 30. Higher-frequency dosing is institutional. Some serious infections with CrCl <50 or IHD may instead use every-12-hour dosing after ID pharmacy review.

Skin infection or CAP with low MRSA risk - IV
CrCl, mL/min	Source-specific dose / instruction
>50	600 mg every 12 hours
30-50	400 mg every 12 hours
15-30	300 mg every 12 hours
<15	200 mg every 12 hours

Severe infection / suspected or documented MRSA pneumonia - IV
CrCl, mL/min	Source-specific dose / instruction
>50	600 mg every 8 hours
30-50	400 mg every 8 hours
15-30	300 mg every 8 hours
<15	200 mg every 8 hours

Dialysis guidance - separate source-specific schedules

Ceftaroline - dialysis
Dialysis setting / indication	Source-specific schedule
IHD - first indication group	200 mg every 12 hours
IHD - severe infection	200 mg every 8 hours
Continuous HD - first indication group	400 mg every 12 hours
Continuous HD - severe infection	600 mg every 12 hours

Read the retained text before reformatting

CrCl bands >50 / 30-50 / 15-30 / <15 mL/min correspond to IV doses 600 / 400 / 300 / 200 mg. For skin infection or community-acquired pneumonia with low MRSA risk, give every 12 hours. For severe infection or pneumonia with suspected/documented MRSA, this institutional regimen uses every 8 hours. The source overlaps at 30.

Intermittent HD: 200 mg every 12 hours for the first group or every 8 hours for severe infection. Continuous HD: 400 mg every 12 hours for the first group or 600 mg every 12 hours for severe infection. Some serious infections with CrCl <50 or IHD may use every-12-hour dosing after ID pharmacy review. The higher-frequency strategy is source-specific.

RDM30-041-ceftaroline-1 · Source locator: UCSF - ceftaroline: standard and severe-infection schedules; renal/dosing sections and stated qualifiers

Source identity and provenance

Source: https://idmp.ucsf.edu/content/ceftaroline
Retrieved: 2026-09-05
Renal-function method: CrCl in mL/min where specified; no equation inferred.
Source date/version: Revision date not stated in the reviewed page.
Hash meaning: Locally authored summary text; not original SPL, HTML or PDF bytes
Local summary SHA-256: 94f03f3b747f167199b2721687b95102008fc4b89f5cec0da6885c0d6f497b1b

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 1 RX List, 1 professional, 0 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source: https://globalrph.com/renal/ceftaroline/
Source retrieval: 2026-09-05. This is not the source publication or label revision date.
Original source type: globalrph individual
Local text SHA-256: 7e3b6ca10768863016fb9e9ebb538bee2daab5bb8a7ccc96a133991b901aaadd
Import versus clinical validation: Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report

Renal guidance at a glance

Teflaro - labeled renal guidance

Renal action and limits

Renal guidance: 2, adult renal impairment dosing table

Read source findings

Teflaro - labeled renal guidance

Teflaro - selected RX renal passage

Evidence sources and renal implications

Preserved original GlobalRPh source

Teflaro - labeled renal guidance

Teflaro - selected RX renal passage

UCSF - ceftaroline: standard and severe-infection schedules

Confirm the exact formulation before using a renal source

Source-specific review points

Search the stored clinical text

Check the setting. Compare whole sources.

Source-by-source comparison

Source differences and product cautions

Teflaro - product and source limitations

Renal dosing and precautions

Teflaro - labeled renal guidance

Teflaro - selected RX renal passage

UCSF - ceftaroline: standard and severe-infection schedules

Original GlobalRPh protocol and comments

Compare or copy source versions

Original GlobalRPh protocol

Indications and usage

Usual Dosing (Adults)

Renal Dosing

Hemodialysis

FDA / DailyMed dosing and renal information

Teflaro - labeled renal guidance

Renal guidance: 2, adult renal impairment dosing table

GlobalRPh RX List renal information

Teflaro - selected RX renal passage

RX List: selected renal passage

University and professional protocols

UCSF - ceftaroline: standard and severe-infection schedules

Dosing / renal protocol and limits

Provenance and preservation